All In Biotech

Drug Trial Radar · NCT07881120

Study of Afimetoran in Adults With Cutaneous Lupus Erythematosus

A 2-Stage Operationally Seamless Phase 2/3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Afimetoran in Participants With Active Cutaneous Lupus Erythematosus With or Without Systemic Manifestations and Refractory and/or Intolerant to Antimalarial Therapy

Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 390 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

390

Planned (sponsor's estimate)

Start

Nov 3, 2026

Primary completion

Apr 2030

Study completion Apr 2031

Sponsor

Lead sponsor
Beeline Medicines CorporationIndustry
Sponsor type
Industry
First posted
Oct 19, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 16 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is evaluating whether afimetoran, an investigational oral medicine that blocks toll-like receptors 7 and 8 (TLR7/TLR8), can improve skin disease in adults with active cutaneous lupus erythematosus (CLE), with or without systemic lupus, whose disease has not responded to or who cannot tolerate antimalarial therapy. Participants are assigned by chance to receive afimetoran or a matching placebo capsule once daily for 24 weeks, in addition to their existing standard lupus care. Neither participants nor study staff know which treatment is given. The study is run in two stages under a single protocol. Stage 1 compares two doses of afimetoran with placebo to select the dose. Stage 2 compares the selected afimetoran dose with placebo to confirm efficacy and safety. After the 24-week placebo-controlled period, all participants receive afimetoran for a further 28 weeks, for a total of 52 weeks of treatment. The main measures of benefit are the change in the CLASI-A skin activity score and the proportion of participants achieving a 70% improvement in that score at Week 24.

Conditions

  • Cutaneous Lupus Erythematosus (CLE)
  • Systematic Lupus Erythematosus

Interventions

  • AfimetoranDrug

    Afimetoran (BLN-256) oral capsule, once daily

  • PlaceboDrug

    Placebo (capsule matched to afimetoran), once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent change from baseline in CLASI-A total scoreTime frame: Baseline to Week 24
  2. Proportion of participants achieving a CLASI-70 response (≥70% decrease from baseline in CLASI-A total score)Time frame: Week 24

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • University Clinical Trials

    San Diego, California · Recruiting

  • Omega Research DeBary, LLC

    DeBary, Florida · Recruiting

  • Boeson Research MSO

    Missoula, Montana · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.